PCOS weight loss without GLP-1s: what metformin can and can't do

What's this video probably claiming?

Based on the caption and hashtags, @marewood is likely sharing a personal story about managing PCOS-related weight gain using metformin instead of semaglutide (Ozempic) or another GLP-1 receptor agonist. The framing, "without ozempic," positions this as a counter-narrative to the current GLP-1 hype cycle, which is understandable given how aggressively GLP-1 drugs have dominated the weight loss conversation. She's probably describing lifestyle changes alongside metformin, crediting the combination with meaningful weight loss, and advocating for herself within a medical system that often dismisses PCOS symptoms. That self-advocacy framing is genuinely important. But the implicit claim, that metformin is a reliable weight loss tool for women with PCOS, deserves a harder look than a TikTok caption can give it.

What does the science actually show?

Metformin is FDA-approved for type 2 diabetes, not PCOS or weight loss. Its use in PCOS is entirely off-label, based on its insulin-sensitizing effects. The evidence for weight loss specifically is underwhelming. A 2012 Cochrane review by Tang et al. found metformin produced modest reductions in BMI compared to placebo in women with PCOS, but the effect sizes were small and inconsistent across trials. A more recent 2023 meta-analysis in Human Reproduction Update (Fraison et al.) confirmed metformin improves insulin resistance, menstrual regularity, and androgen levels, but weight loss outcomes were variable and generally modest, averaging 1 to 2 kg over 6 months. That's not nothing, but it's not a transformation drug. Compare that to semaglutide at 2.4 mg weekly, which produced an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM). The mechanisms are genuinely different.

Where does the social media noise diverge from clinical reality?

The PCOS TikTok space tends to flatten a complicated hormonal condition into a simple narrative: insulin resistance causes weight gain, metformin fixes insulin resistance, therefore metformin causes weight loss. That chain has real logic in it, but it skips several steps. Not all women with PCOS have significant insulin resistance. Phenotypes vary widely, and metformin's benefit is most pronounced in the insulin-resistant subgroup. Beyond that, lifestyle intervention, meaning diet quality and exercise, consistently outperforms metformin alone in head-to-head trials. A 2006 RCT by Knowler-adjacent researchers (Hoeger et al., Fertility and Sterility) found lifestyle modification produced greater improvements in menstrual cyclicity and weight than metformin alone. The "without Ozempic" framing also inadvertently sets up a false binary. These aren't moral choices between pharmaceuticals. They're clinical tools with different evidence bases and different patient profiles.

What should you actually know?

If you have PCOS and you're thinking about metformin for weight management, a few things matter. First, your phenotype matters. Metformin works better if you actually have insulin resistance, which requires lab confirmation, not just a PCOS diagnosis. Second, metformin doses used in PCOS research typically range from 1,000 to 2,000 mg per day, usually titrated slowly to reduce GI side effects. Third, it's not a replacement for GLP-1 therapy in patients who need meaningful weight loss for metabolic health. Some women with PCOS will genuinely need a GLP-1 agonist, and framing that as a failure or capitulation to pharma doesn't serve anyone. Self-advocacy is real and important in PCOS care, where dismissal is common. But advocacy works best when it's informed by actual clinical data, not just community consensus on TikTok.